Bristol-Myers Squibb Company
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0R1F.IL | BIIB | ABBV | AMGN | LLY | PFE | |
|---|---|---|---|---|---|---|
| Market cap | 137.59B | 37.61B | 521.00B | 258.68B | 1.26T | 175.50B |
| P/E (TTM) | 17.3 | 110.2 | 50.7 | 27.7 | 46.0 | 44.0 |
| Forward P/E | — | 15.6 | 18.2 | 19.5 | 28.3 | 10.6 |
| Price/book | 4.2 | 2.0 | -113.7 | 18.0 | 31.4 | 2.1 |
| Dividend yield | 4.04% | — | 2.35% | 2.11% | 0.49% | 5.59% |
| 1-year change | +34.05% | +62.35% | +34.60% | +51.61% | +51.26% | +23.90% |
| Today | +2.89% | +2.22% | +3.09% | +3.73% | +0.61% | +2.63% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All 0R1F.IL news ›Bristol Myers Squibb Company $BMY Stock Holdings Raised by Rakuten Investment Management Inc.
MarketBeat Bristol Myers Squibb Company $BMY Stock Holdings Raised by Rakuten Investment Management Inc. - Rakuten Investment Management increased its Bristol Myers Squibb stake by 9.6% in the third quarter
What Could Derail Bristol Myers Squibb Stock?
Bristol Myers Squibb (BMY) stock returned 42.9% over the past year, compared to 11.5% for the S&P 500. If you own the stock, you want to know what could take some of that gain back, and management has already pointed to pressure on its…
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing openPR.com Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma,…
Bausch Health Cos (NYSE:BHC) & Bristol Myers Squibb (NYSE:BMY) Head-To-Head Comparison
Posted by Sarita Garza on Nov 4th, 2026 Bristol Myers Squibb (NYSE:BMY – Get Free Report) and Bausch Health Cos (NYSE:BHC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies…
Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, AstraZeneca, Sanofi, Amgen
Albany New York November 03 2026 As per DelveInsight s assessment globally Cutaneous Lupus Erythematosus pipeline constitutes 8 key companies continuously working towards developing 10 Cutaneous Lupus Erythematosus treatment therapies…
Tempus AI, Inc. Enters Into Multi-Year Agreement With Bristol Myers Squibb To License Multimodal Oncology Data
Tempus AI, Inc. announced a multi-year agreement with Bristol Myers Squibb, under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight... announced a multi-year agreement with…
Total common shares outstanding of Bristol-Myers Squibb Company Shs Canadian Depositary Receipt Repr Shs Reg S – FWB:BRM0
Total common shares outstanding of Bristol-Myers Squibb Company Shs Canadian Depositary Receipt Repr Shs Reg TradingView Bristol-Myers Squibb Company Shs Canadian Depositary Receipt Repr Shs Reg S Total common shares outstanding of…
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown. Is your portfolio ready for the shifting landscape of modern medicine?…
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at the US price, a first for the company
Science Firsthand: Making the leap to intentionally designed degraders How we orchestrate clinical trials to deliver hope for patients Building a more resilient energy future to support patients Bringing life-saving medicines to more…
Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data
[IMAGE CREDIT: Robert Kneschke via Canva] Tempus AI (TEM) is up 6% today after Bristol Myers Squibb (BMY) signed a multi-year deal to license Tempus’s oncology data through 2031. Tempus says BMS now “becomes one of Tempus’s largest…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com25
- fool.com18
- marketbeat.com18
- theglobeandmail.com15
- themarketsdaily.com12
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.